OBJECTIVES: The newly-introduced glatiramer acetate (GA; COPAXONE^®) 40 mg/ml three times a week maintains the known efficacy and safety of GA 20 mg/ml once-daily but requires around 200 fewer injections per year (60% fewer) for people treated for relapsing forms of multiple sclerosis (MS).  An economic model with a five-year time horizon estimated the financial impact to the Spanish healthcare system of reduced switching from GA-based regimens to more expensive newly-introduced first-line disease modifying therapies (DMTs) and the second-line DMTs. METHODS: The eligible population was based on 2014 Spanish MS incidence rates, with the proportion receiving DMTs calculated using market research data.  Medication costs were based on known Spanish prices, while treatment initiation, administration and monitoring costs were calculated from published Spanish sources and Summary of Product Characteristics documentation.  Switching rates and future treatment patterns were based on manufacturer’s projections.   RESULTS: An estimated 5,084 people with MS received GA 20 mg/ml once-daily in Spain in 2014 (12.1% of those receiving DMTs) and were assumed to switch to more expensive newly-introduced first-line and second-line DMTs at an annual rate of 8%.  Assuming these people received GA 40 mg/ml three times a week instead, and – due to requiring fewer injections – switched at an annual rate of 5%, total expenditure on DMTs and related costs was reduced by between €5.9 million and €7.2 million annually, with savings totalling €32.8 million over five years: a 21% reduction in total expenditure related to DMTs included in the model, compared with GA 20 mg/ml once-daily.  Savings were primarily driven by lower acquisition costs of GA compared with other DMTs, and also from lower initiation, administration and monitoring requirements.  CONCLUSIONS: Introducing GA 40 mg/ml three times a week may limit switching from GA to more expensive newly-introduced first- and second-line DMTs, potentially generating cost savings.